AcelRx Pharma Poised to Move Higher on Technicals and Latest News

$ACRX Trade Call – Target $5.75

Yesterday, AcelRX said its Sufentanil NanoTab patient-controlled analgesia (PCA) system, showed that it helped reduce pain significantly compared with a placebo.

Patients in the study were treated with AcelRx’s system for post-operative pain for a minimum of 48 hours and up to 72 hours.

With the handheld NanoTab PCA system, AcelRx is seeking to win approval for a non-invasive way for patients to self-dose the FDA-approved pain drug sufentanil.

 

Acel is very undervalued per its current $119.12M market cap, and the chart below indicates a move coming soon to the $6 level in my opinion.

Accumulation, MACD and RSI are trending upwards per the 3 day 10 minute chart above.

Lots of good things ahead for ACRX. I think my $5.75 target is low like it was for $TSRX

Click Here to register for free on Investors Hub

Follow @stockmatusow

This area of the investorshub.advfn.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of Investors Hub. Investors Hub does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at Investors Hub is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by investorshub.advfn.com and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.

Comments are closed

• 

  Fiona Craig

• 

  Andre Minassian

• 

  scottmatusow1

• 

  Ed Liston